Noticias sobre VIH/SIDA
Top 5 HIV treatment stories from CROI 2024
The Conference on Retroviruses and Opportunistic Infections (CROI 2024) took place this month. Researchers presented work on new and existing HIV treatment options. Here are some of the highlights.
Categorías: VIH/SIDA
ONUSIDA insta a ampliar los servicios basados en pruebas para abordar la transmisión del VIH y la hepatitis viral entre las personas que consumen drogas
En la 67.ª reunión de la Comisión de Narcóticos de las Naciones Unidas que se celebra en Viena, ONUSIDA ha solicitado la ampliación urgente de los servicios para prevenir nuevas infecciones por el VIH y la hepatitis viral entre las personas que consumen drogas. Dirigiéndose a los delegados en su mensaje en vídeo, la directora ejecutiva de ONUSIDA, Winnie Byanyima, elogió a algunos países por hacer progresos en la implementación de programas basados en pruebas, pero pidió una acción más audaz.
Categorías: VIH/SIDA
ONUSIDA insta a ampliar los servicios basados en pruebas para hacer frente a la transmisión del VIH y la hepatitis viral entre los consumidores de drogas
En la 67ª reunión de la Comisión de Estupefacientes de las Naciones Unidas que se celebra en Viena, ONUSIDA ha hecho un llamamiento para que se amplíen urgentemente los servicios de prevención de nuevas infecciones por el VIH y la hepatitis vírica entre los consumidores de drogas. Dirigiéndose a los delegados en su mensaje de vídeo, la Directora Ejecutiva de ONUSIDA, Winnie Byanyima, elogió a algunos países por los progresos realizados en la aplicación de programas basados en pruebas, pero hizo un llamamiento para que se tomen medidas más audaces.
Categorías: VIH/SIDA
Semaglutide improves fatty liver disease and inflammation in people with HIV
Semaglutide, best known as a weight-loss medication, reduced liver fat build-up and appears to lower inflammation in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD), according to study results presented last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2024).
Categorías: VIH/SIDA
Women with HIV need tailored advice on statins and heart disease risk
Counselling about heart disease risk and statin use for women with HIV should highlight the similar levels of risk for men and women with HIV when communicating the results of the REPRIEVE study, one of the study’s investigators told the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver last week.
Advice also needs to make women aware of how the symptoms of heart disease differ in women and men.
[GLOSSARY]
Categorías: VIH/SIDA
Progress in reducing new HIV diagnoses much slower for Black men in the US
Lifetime risk of acquiring HIV has decreased for Black gay and bisexual men in the US, from 1 in 2 from 2010 to 2014 to 1 in 3 from 2017 to 2021, according to data presented to the Conference on Retroviruses and Opportunistic Infections (CROI 2024) by researchers from the US Centers for Disease Control and Prevention (CDC) last week.
Categorías: VIH/SIDA
The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance become a problem?
A number of presentations at last week’s Conference on Retroviruses and Opportunistic Infections (CROI 2024) looked at whether HIV is starting to develop resistance to dolutegravir, one of the most widely used antiretrovirals in the world.
Categorías: VIH/SIDA
Ultra-long-acting cabotegravir could be taken three times a year for HIV PrEP and treatment
An longer-acting formulation of cabotegravir may offer an HIV pre-exposure prophylaxis (PrEP) and treatment option that could be administered once every four months, according to early study results presented last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2024).
Categorías: VIH/SIDA
HIV medication dolutegravir not linked with increased blood pressure during pregnancy
Dolutegravir did not increase the risk of high blood pressure during pregnancy in a large international study, but mildly raised blood pressure was common in young women with HIV, Professor Risa Hoffman reported on behalf of the IMPAACT 2010 study team at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver last week.
Categorías: VIH/SIDA
Switch to an integrase inhibitor leads to greater weight during and after the menopause
Switching to an integrase inhibitor around the time of the menopause was associated with accelerated weight gain in women with HIV when compared to pre-menopausal women with HIV, a retrospective cohort study has found.
The study, conducted in the United States, was presented last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver by Dr Rebecca Abelman of University of California San Francisco.
Categorías: VIH/SIDA
Huge increase in PrEP uptake when services offer choice, flexibility <i>and</i> injectable PrEP, African study shows
A programme in rural Kenya and Uganda that has already demonstrated that a dynamic, person-centred HIV prevention intervention results in substantial increases in the numbers of people covered by PrEP or PEP, has now shown the added benefits of offering a choice between PrEP pills and PrEP injections.
Categorías: VIH/SIDA
Far fewer HIV infections in Australian PrEP users – consistent use is key
An impressive 79% reduction in HIV incidence was seen between two directly comparable groups in a whole-population analysis from Australia, presented to the Conference on Retroviruses and Opportunistic Infections (CROI 2024) this week by Dr Nicholas Medland.
People who have received hepatitis C treatment and who were not adherent to PrEP were particularly vulnerable to acquiring HIV within a few years of receiving their first PrEP prescription.
Categorías: VIH/SIDA
Some children who start antiretrovirals very early may control HIV after stopping treatment
A small proportion of children who start HIV treatment within the first two days of life may achieve ongoing viral suppression after stopping antiretrovirals, according to study results presented yesterday at the Conference on Retroviruses and Opportunistic Infections (CROI 2024). While these promising findings hold clues for HIV cure research, such early therapy is out of reach for many, and treatment interruption remains risky without careful monitoring.
Categorías: VIH/SIDA
Prostate cancer diagnosed later in US men with HIV
Men with HIV in the US’s largest care provider for people with HIV were more likely to be diagnosed late with prostate cancer and less likely to undergo testing that may warn of an increased prostate cancer risk, the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver heard this week.
Categorías: VIH/SIDA
People-centred blood pressure management improves blood pressure in people with HIV
Three studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver this week showed that innovative service models can successfully deliver drug treatment for high blood pressure to people with HIV through HIV clinics or community health workers, and reduce blood pressure.
Categorías: VIH/SIDA
Six-country African PrEP study achieves high levels of persistence and good adherence in young women
A demonstration project of oral PrEP for young women, conducted in six African countries with high HIV prevalence, achieved high levels of PrEP uptake and persistence, and good levels of adherence among its 3000 participants.
Categorías: VIH/SIDA
Islatravir plus lenacapavir could be the first once-weekly oral HIV treatment
A once-weekly oral regimen can keep HIV suppressed as well as daily pills, according to study results presented today at the Conference on Retroviruses and Opportunistic Infections (CROI 2024).
Categorías: VIH/SIDA
Broadly neutralising antibodies may be partners for long-acting antiretrovirals
Two long-acting antiretrovirals, lenacapavir (Sunlenca) and cabotegravir (Vocabria), may pair well with broadly neutralising antibodies for HIV treatment, according to two presentations yesterday at the Conference on Retroviruses and Opportunistic Infections (CROI 2024).
Categorías: VIH/SIDA
HIV diagnoses continue to fall in US states with high PrEP coverage, while others are left behind
The number of new HIV diagnoses has continued to drop steeply between 2012 and 2021 in US states with the highest coverage of PrEP (regular medication to prevent HIV), according to research presented by Dr Patrick Sullivan at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) yesterday.
Categorías: VIH/SIDA
Once-weekly antiretrovirals on the horizon
Two antiretrovirals with the potential for once-weekly oral dosing were unveiled at CROI 2024 in Denver on Monday.
The new agents have undergone phase 1 studies, which establish appropriate dosing and weed out drugs which have serious side effects. Before becoming available for prescription, drugs go through two further phases of testing to establish their efficacy, dosing and safety. During these stages of development many products fall by the wayside either because unexpected problems arise or the commercial priorities of the pharmaceutical company change.
Categorías: VIH/SIDA